תוכנית

20:00 - 20:05

Opening Remarks

Dr.Henit Yanai

Head of the IBD Center, the Division of Gastroenterology
Rabin Medical Center: Chair of the Israeli IBD Society

20:05 - 20:45

Hyrimoz Clinical Data including Real World Evidence and experirnce

Prof. Gionata Fiorino

Clinical Researcher
and Gastroenterologist at Vita-Salute San Raffaele University
and Hospital, Milan, Leading Clinical Researcher at IBD Clinical
Trail Unit,
San Camillo – Forlanini Hospital, Roma, Italy

20:45 - 21:00

Q&A session

Moderated by Dr.Henit Yanai

הרשמה לוובינר

הרשמה לצוותים רפואיים

ההרשמה הינה ללא עלות ומיועדת לפנימאים, גסטרואנטרולוגים, רופאי משפחה , רופאי עור וראומטולוגים

Hyrimoz Therapeutic Indications
Rheumatoid arthritis: Hyrimoz in combination with methotrexate, is indicated for: • the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate. • the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate. Hyrimoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate. Juvenile idiopathic arthritis: Polyarticular juvenile idiopathic arthritis: Hyrimoz in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Hyrimoz can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in patients aged less than 2 years. Enthesitis-related arthritis: Hyrimoz is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy. Axial spondyloarthritis: Ankylosing spondylitis (AS): Hyrimoz is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy. Axial spondyloarthritis without radiographic evidence of AS: Hyrimoz is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS, but with objective signs of inflammation by radiological and/or laboratory tests including MRI and serum CRP levels , who have had an inadequate response to, or are intolerant to, non – steroidal anti-inflammatory drugs. Psoriatic arthritis: Hyrimoz is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease and to improve physical function. Psoriasis: Hyrimoz is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. Paediatric plaque psoriasis: Hyrimoz is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies. Hidradenitis suppurativa (HS): Hyrimoz is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.Crohn’s disease: Hyrimoz is indicated for reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy. Hyrimoz is indicated for reducing signs and symptoms and inducing clinical remission in these patients if they have also lost response to or are intolerant to infliximab. Paediatric Crohn's disease: Hyrimoz is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6- years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and corticosteroid, and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies. Ulcerative colitis: Hyrimoz is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. Uveitis: Hyrimoz is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate. Paediatric Uveitis: Hyrimoz is indicated for the treatment of chronic non-infectious uveitis in paediatric patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. Intestinal Behcet’s disease: Hyrimoz is indicated for the treatment of intestinal Behcet’s disease in patients who have had an inadequate response to conventional therapy

 

 

HYR-LAN-18.22 Nov-2022

Dear Physician, for further information please refer to the prescribing information click here

and patient leaflet click here as approved by the Israeli Ministry of Health

נוברטיס ישראל בע"מ

תוצרת הארץ 6. תל אביב,

ת.ד. 7126, טל. 03-9201111